IP Library › Granted Patent US 12,460,255
Granted Patent B2
US 12,460,255 · App. 18/146,508 · Granted Nov 4, 2025

Compositions and methods to detect adenovirus nucleic acids and metapneumovirus and/or rhinovirus nucleic acids

Inventors: Mehrdad R. Majlessi (Escondido, CA); Ankur Shah (San Diego, CA); Amber Hillius (San Diego, CA); Pamela Douglass (Kansas City, MO); Daniel Kolk (Ramona, CA)
Assignee: GEN-PROBE INCORPORATED
C12Q1/6844C12Q1/701C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,460,255
App. No.
18/146,508
Granted
Nov 4, 2025
Kind
B2
Abstract

The disclosed disclosure is related to methods, compositions, and kits for targeting Adenovirus, Metapneumovirus, and/or Rhinovirus nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers. Kits and methods comprise at least one of these oligomers. Methods include uniplex and multiplex amplification and detection reactions.

Claims (104)

1 . A composition comprising a combination of amplification oligomers configured for amplification of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, wherein:

(A) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs: 1, 5, 11, 12, 25, 26, 31 to 34, 35, 38, and 71 to 74, and a second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs: 2, 3, 6 to 9, 13 to 16, 27, 28, 42 to 46, 61, 62, and 138 to 149; and

(B) for the at least one additional target nucleic acid,

(1) (a) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 880 to 915 of SEQ ID NO:159and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 953 to 995 of SEQ ID NO:159; or

(b) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1000 to 1040 of SEQ ID NO:150 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1073 to 1115 of SEQ ID NO:150; and/or

(2) (a) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 263 to 303 of SEQ ID NO:120 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 480 to 533 of SEQ ID NO:120; or

(b) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 231 to 264 of SEQ ID NO:101 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 455 to 506 of SEQ ID NO:101; or

(c) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 106 to 156 of SEQ ID NO:76 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 338 to 397 of SEQ ID NO:76.

2 . The composition of claim 1 , further comprising an Adenovirus detection probe oligomer comprising a sequence that is from 18 to 36 nucleobases in length wherein the 18 to 36 nucleobases are all selected from contiguous nucleobases within SEQ ID NO:138, wherein the Adenovirus detection probe oligomer comprises at least one of

(i) a detectable label,

(ii) a substitution at the 2′ position of at least one ribose moiety,

(iii) a blocking moiety at or within five residues of the 3′ end of the detection probe oligomer, wherein the blocking moiety is configured to prevent enzyme-mediated extension of the detection probe in an amplification reaction, and

(iv) a non-target-hybridizing sequence that contributes to the three-dimensional conformation of the detection probe oligomer.

3 . The composition of claim 1 , further comprising

(a) a Metapneumovirus detection probe oligomer configured to hybridize to a region of the Metapneumovirus amplicon, if the first and second Metapneumovirus amplification oligomers are present, and/or

(b) a Rhinovirus detection probe oligomer configured to hybridize to a region of the Rhinovirus amplicon, if the first and second Rhinovirus amplification oligomers are present.

4 . The composition of claim 1 , wherein

the first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74; and/or

the second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62.

5 . The composition of claim 4 , wherein

the first Adenovirus amplification oligomer comprises the target hybridizing sequence of SEQ ID NO:71; and

the second Adenovirus amplification oligomer comprises the target hybridizing sequence of SEQ ID NO:62.

6 . The composition of claim 1 , wherein the composition comprises the first and second Metapneumovirus amplification oligomers, wherein

the first Metapneumovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:52, 53, 151, 152, 153, 154, and 160; and/or

the second Metapneumovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:56, 68, 158, 177, and 178.

7 . The composition of claim 1 , wherein the composition comprises the first and second Rhinovirus amplification oligomers, wherein

the first Rhinovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:50, 51, 59, 60, 65, 75, 77 to 86, 102 to 108, and 121 to 130; and/or

the second Rhinovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:57, 95 to 100, 115 to 119, and 137.

8 . A dried composition comprising:

(A) a combination of amplification oligomers configured for amplification of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, wherein

(1) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:1, 5, 11, 12, 25, 26, 31 to 34, 35, 38, and 71 to 74, and a second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:2, 3, 6 to 9, 13 to 16, 27, 28, 42 to 46, 61, 62, and 138 to 149; and

(2) for the at least one additional target nucleic acid,

(a) (i) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 880 to 915 of SEQ ID NO:159 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 953 to 995 of SEQ ID NO:159; or

(ii) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1000 to 1040 of SEQ ID NO:150 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1073 to 1115 of SEQ ID NO:150; and/or

(b) (i) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 263 to 303 of SEQ ID NO:120 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 480 to 533 of SEQ ID NO:120; or

(ii) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 231 to 264 of SEQ ID NO:101 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 455 to 506 of SEQ ID NO:101; or

(iii) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 106 to 156 of SEQ ID NO:76 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 338 to 397 of SEQ ID NO:76;

(B) an inorganic salt;

(C) a polymerase enzyme having 5′ to 3′ exonuclease activity;

(D) a reverse transcriptase; and

(E) dNTPs.

9 . The dried composition of claim 8 , further comprising an Adenovirus detection probe oligomer configured to hybridize to a region of the Adenovirus amplicon, wherein the Adenovirus detection probe oligomer comprises at least one of

(i) a detectable label,

(ii) a substitution at the 2′ position of at least one ribose moiety,

(iii) a blocking moiety at or within five residues of the 3′ end of the detection probe oligomer, wherein the blocking moiety is configured to prevent enzyme-mediated extension of the detection probe in an amplification reaction, and

(iv) a non-target-hybridizing sequence that contributes to the three-dimensional conformation of the detection probe oligomer.

10 . The dried composition of claim 8 , further comprising

(a) a Metapneumovirus detection probe oligomer configured to hybridize to a region of the Metapneumovirus amplicon, if the first and second Metapneumovirus amplification oligomers are present, and/or

(b) a Rhinovirus detection probe oligomer configured to hybridize to a region of the Rhinovirus amplicon, if the first and second Rhinovirus amplification oligomers are present.

11 . The dried composition of claim 8 , wherein

the first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74; and/or

the second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62.

12 . The dried composition of claim 11 , wherein

the first Adenovirus amplification oligomer comprises the target hybridizing sequence of SEQ ID NO:71; and

the second Adenovirus amplification oligomer comprises the target hybridizing sequence of SEQ ID NO:62.

13 . The dried composition of claim 8 , wherein the dried composition comprises the first and second Metapneumovirus amplification oligomers, wherein

the first Metapneumovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:52, 53, 151, 152, 153, 154, and 160; and/or

the second Metapneumovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:56, 68, 158, 177, and 178.

14 . The dried composition of claim 8 , wherein the dried composition comprises the first and second Rhinovirus amplification oligomers, wherein

the first Rhinovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:50, 51, 59, 60, 65, 75, 77 to 86, 102 to 108, and 121 to 130; and/or

the second Rhinovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:57, 95 to 100, 115 to 119, and 137.

15 . A formulation for amplification and detection of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, the formulation comprising:

(A) a combination of amplification oligomers configured for amplification of the Adenovirus target nucleic acid and at least one additional target nucleic acid, wherein

(1) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:1, 5, 11, 12, 25, 26, 31 to 34, 35, 38, and 71 to 74, and a second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:2, 3, 6 to 9, 13 to 16, 27, 28, 42 to 46, 61, 62, and 138 to 149;and

(2) for the at least one additional target nucleic acid,

(a) (i) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 880 to 915 of SEQ ID NO:159 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 953 to 995 of SEQ ID NO:159; or

(ii) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1000 to 1040 of SEQ ID NO:150 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1073 to 1115 of SEQ ID NO:150; and/or

(b) (i) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 263 to 303 of SEQ ID NO:120 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 480 to 533 of SEQ ID NO:120; or

(ii) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 231 to 264 of SEQ ID NO:101 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 455 to 506 of SEQ ID NO:101; or

(iii) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 106 to 156 of SEQ ID NO:76 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 338 to 397 of SEQ ID NO:76;

(B) a combination of detection probe oligomers comprising

(1) an Adenovirus detection probe oligomer comprising a sequence that is from 18 to 36 nucleobases in length wherein the 18 to 36 nucleobases are all selected from contiguous nucleobases within SEQ ID NO:138; and

(2) at least one additional detection probe oligomer comprising

(a) a Metapneumovirus detection probe oligomer configured to hybridize to a region of the Metapneumovirus amplicon, if the first and second Metapneumovirus amplification oligomers are present; and/or

(b) a Rhinovirus detection probe oligomer configured to hybridize to a region of the Rhinovirus amplicon, if the first and second Rhinovirus amplification oligomers are present;

(E) a polymerase enzyme having 5′ to 3′ exonuclease activity;

(F) a reverse transcriptase;

(G) dNTPs;

(H) EDTA; and

(I) water.

16 . The formulation of claim 15 , wherein each of the detection probe oligomers comprises a detectable label.

17 . The formulation of claim 16 , wherein each of the detection probe oligomers is a dual labeled detection probe oligomer comprising a fluorescent detectable label and a quencher moiety that can quench a fluorescent emission from the fluorescent label.

18 . The formulation of claim 15 , wherein the first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs: 71, 72, 73, and 74; and/or

the second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62.

19 . The formulation of claim 18 , wherein

the first Adenovirus amplification oligomer comprises the target hybridizing sequence of SEQ ID NO:71; and

the second Adenovirus amplification oligomer comprises the target hybridizing sequence of SEQ ID NO:62.

20 . The formulation of claim 15 , wherein the formulation comprises the first and second Metapneumovirus amplification oligomers, wherein

the first Metapneumovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:52, 53, 151, 152, 153, 154, and 160; and/or

the second Metapneumovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:56, 68, 158, 177, and 178.

21 . The formulation of claim 15 , wherein the formulation comprises the first and second Rhinovirus amplification oligomers, wherein

the first Rhinovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:50, 51, 59, 60, 65, 75, 77 to 86, 102 to 108, and 121 to 130; and/or

the second Rhinovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:57, 95 to 100, 115 to 119, and 137.

22 . A method for determining the presence or absence of an Adenovirus target nucleic acid and at least one additional target nucleic acid in a sample, wherein the at least one additional target nucleic acid is selected from a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, the method comprising the steps of:

(A) contacting the sample with a combination of amplification oligomers configured for amplification of the Adenovirus and at least one additional target nucleic acids, wherein:

(1) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:1, 5, 11, 12, 25, 26, 31 to 34, 35, 38, and 71 to 74, and a second Adenovirus amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:2, 3, 6 to 9, 13 to 16, 27, 28, 42 to 46, 61, 62, and 138 to 149; and

(2) for the at least one additional target nucleic acid,

(a) (i) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 880 to 915 of SEQ ID NO:159 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 953 to 995 of SEQ ID NO:159; or

(ii) a first Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1000 to 1040 of SEQ ID NO:150 and a second Metapneumovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 1073 to 1115 of SEQ ID NO:150; and/or

(b) (i) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 263 to 303 of SEQ ID NO:120 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least about 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 480 to 533 of SEQ ID NO:120; or

(ii) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 231 to 264 of SEQ ID NO:101 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 455 to 506 of SEQ ID NO:101; or

(iii) a first Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 106 to 156 of SEQ ID NO:76 and a second Rhinovirus amplification oligomer comprises a target hybridizing sequence that is at least 10 nucleotides in length and complementary to contiguous nucleotides within nucleotide positions 338 to 397 of SEQ ID NO:76;

(B) performing an in vitro nucleic acid amplification reaction wherein any of the Adenovirus target nucleic acid and at least one additional target nucleic acid, if present in the sample, is used by the combination of amplification oligomers to amplify that target nucleic acid to generate an amplification product; and

(C) detecting the amplification product; thereby determining the presence or absence of the Adenovirus target nucleic acid and at least one additional target nucleic acid in the sample.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 065286/0407 Recorded Apr 24, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE PRODESSE, INC.
Reel/Frame 075457/0767 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2024
From: MAJLESSI, MEHRDAD R.; SHAH, ANKUR; HILLIUS, AMBER; DOUGLAS, PAMELA; KOLK, DANIEL P.
To: GEN-PROBE INCORPORATED
Reel/Frame 066755/0311 →
SECURITY INTEREST Recorded Oct 19, 2023
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 065286/0407 →
Continuity (5)
Continuation 17820256 · Aug 17, 2022
Continuation 17834578 · Jun 7, 2022
Continuation 16497229
Provisional Application 62476753 · Mar 25, 2017
Related Publication 20230203571A1 · Jun 29, 2023
References Cited (58)
US 8318423B2 · Lee et al. · 2012 [cited by applicant]
US 8715922B2 · De Jong et al. · 2014 [cited by applicant]
US 9518303B2 · Pyles et al. · 2016 [cited by applicant]
US 9650685B2 · Lu et al. · 2017 [cited by applicant]
US 10106860B2 · Yoo et al. · 2018 [cited by applicant]
US 11384387B2 · Majlessi et al. · 2022 [cited by applicant]
US 20060003352A1 · Lipkin et al. · 2006 [cited by applicant]
US 20060240412A1 · Hall et al. · 2006 [cited by applicant]
US 20060286580A1 · Lin et al. · 2006 [cited by applicant]
US 20070092871A1 · Lodes et al. · 2007 [cited by applicant]
US 20070099177A1 · Helm · 2007 [cited by applicant]
US 20080102444A1 · Lee et al. · 2008 [cited by applicant]
US 20090105092A1 · Lipkin et al. · 2009 [cited by applicant]
US 20100086908A1 · Prudent et al. · 2010 [cited by applicant]
US 20100143881A1 · Lu et al. · 2010 [cited by applicant]
US 20110097704A1 · Sampath et al. · 2011 [cited by applicant]
US 20110111391A1 · Gonzalez et al. · 2011 [cited by applicant]
US 20120089859A1 · Wang · 2012 [cited by applicant]
US 20130209992A1 · Becker et al. · 2013 [cited by applicant]
US 20140057263A1 · Engel et al. · 2014 [cited by applicant]
US 20140127671A1 · Yoo et al. · 2014 [cited by applicant]
US 20140309138A1 · Poetter et al. · 2014 [cited by applicant]
US 20150099261A1 · Curran et al. · 2015 [cited by applicant]
US 20150211055A1 · Apte et al. · 2015 [cited by applicant]
US 20150284782A1 · Reijans et al. · 2015 [cited by applicant]
US 20160010152A1 · Shafer et al. · 2016 [cited by applicant]
US 20170051364A1 · Lee et al. · 2017 [cited by applicant]
US 20200263242A1 · Majlessi et al. · 2020 [cited by applicant]
CN 105018488A · 2015 [cited by applicant]
CN 106222304A · 2016 [cited by applicant]
ES 2344443A1 · 2010 [cited by applicant]
KR 101749587B1 · 2017 [cited by applicant]
WO 2002067861A2 · 2002 [cited by applicant]
WO 2005100611A2 · 2005 [cited by applicant]
WO 2007130519A2 · 2007 [cited by applicant]
WO 2008016988A1 · 2008 [cited by applicant]
WO 2009009900A1 · 2009 [cited by applicant]
WO 2011079064A1 · 2011 [cited by applicant]
WO 2012046219A2 · 2012 [cited by applicant]
WO 2012089240A1 · 2012 [cited by applicant]
WO 2018183124A1 · 2018 [cited by applicant]
European Search Report dated Sep. 8, 2023 for corresponding European Application 23156298.4 (6 pages). [cited by applicant]
European Search Report dated Sep. 8, 2023 for corresponding European Application 231566456.8 (7 pages). [cited by applicant]
European Search Report mailed Jul. 23, 2024, issued in corresponding European Application No. 24168848.0, filed Mar. 23, 2018, 6 pages. [cited by applicant]
Khodakov et al., “DNA capture-probe based separation of double-stranded polymerase chain reaction amplification products in poly(dimthylsiloxane) microfluidic channels,” Biomicrofluidics 6:026503, 2012. [cited by applicant]
Xu et al., “Species-Specific Identification of Human Adenoviruses by a Multiplex PCR Assay,” J. Clin. Microbiol. 28:4114-4120, Nov. 2000. [cited by applicant]
U.S. Appl. No. 16/497,229, Final Office Action mailed Nov. 8, 2021. [cited by applicant]
U.S. Appl. No. 16/497,229, Non-Final Office Action mailed Apr. 8, 2021. [cited by applicant]
U.S. Appl. No. 16/497,229, Notice of Allowance mailed Mar. 8, 2022. [cited by applicant]
U.S. Appl. No. 16/497,229, Notice of Allowance mailed Apr. 4, 2022. [cited by applicant]
U.S. Appl. No. 16/497,229, Requirement for Restriction/Election mailed Oct. 9, 2020. [cited by applicant]
WIPO Application No. PCT/US2018/024141, International Preliminary Report on Patentability mailed Oct. 1, 2019. [cited by applicant]
WIPO Application No. PCT/US2018/024141, International Search Report and Written Opinion mailed Jul. 25, 2018. [cited by applicant]
Damen et al., “Real-Time PCR with an Internal Control for Detection of All Known Human Adenovirus Serotypes,” J. Clin. Microbiol. 46:3997-4003, 2008; Published Ahead of Print Oct. 15, 2008. [cited by applicant]
Wong et al., “Detection of a Broad Range of Human Adenoviruses in Respiratory Tract Samples Using a Sensitive Multiplex Real-Time PCR Assay,” J. Med. Virol. 80:856-865, 2008. [cited by applicant]
Bochkov, Y.A., et al., “Improved Molecular Typing Assay for Rhinovirus Species A, B, and C,” Journal of Clinical Microbiology 52(7):2461-2471, 2014. [cited by applicant]
Österback, R., et al., “Simultaneous Detection and Differentiation of Human Rhino- and Enteroviruses in Clinical Specimens by Real-Time PCR with Locked Nucleic Acid Probes,” Journal of Clinical Microbiology 51(12):3960-… [cited by applicant]
Zlateva, K.T., et al., “Prolonged shedding of rhinovirus and re-infection in adults with respiratory tract illness,” European Respiratory Journal 44:169-177, 2014. [cited by applicant]